Carbachol - Generic Drug Details

What are the generic sources for carbachol and what is the scope of freedom to operate?

Carbachol is the generic ingredient in three branded drugs marketed by Pharmafair, Novartis, and Alcon, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for carbachol. One supplier is listed for this compound.

Summary for carbachol

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	8
Patent Applications:	7,153
What excipients (inactive ingredients) are in carbachol?	carbachol excipients list
DailyMed Link:	carbachol at DailyMed

Recent Clinical Trials for carbachol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	PHASE2
Visus Therapeutics	Phase 3
Visus Therapeutics	Phase 2

See all carbachol clinical trials

Pharmacology for carbachol

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Agonists

Medical Subject Heading (MeSH) Categories for carbachol

Analgesics, Non-Narcotic

Cardiotonic Agents

Cholinergic Agonists

Miotics

Anatomical Therapeutic Chemical (ATC) Classes for carbachol

N07AB	Choline esters
N07A	PARASYMPATHOMIMETICS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

S01EB	Parasympathomimetics
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for carbachol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmafair	CARBACHOL	carbachol	SOLUTION;INTRAOCULAR	070292-001	May 21, 1986		DISCN	No	No
Novartis	CARBASTAT	carbachol	SOLUTION;INTRAOCULAR	073677-001	Apr 28, 1995		DISCN	No	No
Alcon	MIOSTAT	carbachol	SOLUTION;INTRAOCULAR	016968-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Carbachol

Last updated: February 16, 2026

What is the Current Market Size and Growth Trend for Carbachol?

Carbachol, a muscarinic receptor agonist primarily used for glaucoma treatment and intraocular pressure reduction, remains a niche pharmaceutical. Its market size was valued at approximately $20 million globally in 2022. The compound's market growth rate has been modest, with an average annual increase of about 3-4% over the past five years. This growth is driven by its limited but steady demand in ophthalmology, especially in markets with high glaucoma prevalence, such as Asia and Latin America.

The total addressable market (TAM) is constrained by competition from newer treatments, including prostaglandin analogs and beta-blockers. Sales data indicate that carbachol accounts for less than 2% of the global glaucoma therapeutics market, which was valued at approximately $9 billion in 2022 (source: IQVIA).

How Do Market Drivers and Barriers Influence Carbachol’s Trajectory?

Drivers

• Established Efficacy: As one of the earliest drugs approved for intraocular pressure reduction, its well-documented safety profile sustains demand.
• Cost-Effectiveness: Lower manufacturing costs make it attractive in cost-sensitive markets.
• Regulatory Approvals: It retains approvals in multiple countries, supporting market access.

Barriers

• Competitive Alternatives: Prostaglandin analogs now dominate, offering once-daily dosing and fewer side effects.
• Limited Innovation: There are few efforts for reformulation or new indications.
• Market Shift: Ophthalmologists prefer newer, more convenient drugs, impacting sales volume.

What is the R&D and Patent Landscape Surrounding Carbachol?

Carbachol’s patent protection largely expired by the early 2000s. A handful of companies still manufacture generic formulations, with minimal ongoing R&D focused on new indications or delivery methods. The absence of patent barriers has encouraged generic proliferation but diminishes incentives for innovation.

Market exclusivity and patent cliff effects have kept the drug as a low-margin commodity. No recent filings suggest significant new patents or derivatives in development.

How Is the Financial Performance of the Carbachol Market Expected to Evolve?

• Revenue Trend: Anticipated to decline gradually, averaging 1-2% annually over the next five years, owing to the aging population and stable glaucoma prevalence.
• Profit Margins: Remain low due to generic competition but remain stable for manufacturers with low production costs.
• Potential for Market Expansion: Limited, unless new formulations, combination therapies, or delivery mechanisms are introduced.

What Future Opportunities or Risks Exist in the Carbachol Sector?

Opportunities

• Potential development of sustained-release formulations to improve compliance.
• Expansion into new regional markets with unmet ophthalmic needs.
• Exploration of alternate indications, such as intraocular surgery adjuncts.

Risks

• Regulatory pressures favoring newer, better-tolerated medications.
• Price erosion resulting from widespread generic manufacturing.
• Technological advancements making older drugs obsolete.

---

Key Takeaways

• The global market for carbachol was valued at approximately $20 million in 2022.
• Growth remains slow, constrained by competition from newer glaucoma treatments.
• Patent expiration has led to generic proliferation, limiting profitability.
• Innovation in formulations or new indications could offer growth avenues but remains limited.
• Market decline is expected in the medium term due to competitive and technological factors.

---

FAQs

1. What therapeutic indications does carbachol target?

Carbachol is primarily used to treat glaucoma and reduce intraocular pressure in ophthalmic procedures.

2. How competitive is the market for carbachol?

It is highly competitive with multiple generics available, leading to low profit margins and limited differentiation.

3. Are there efforts to reformulate or improve carbachol?

Research has been minimal; most efforts focus on alternative drugs with better profiles.

4. Can carbachol be used for conditions other than glaucoma?

Limited indications include intraocular surgeries, but these represent a small segment with negligible market impact.

5. What are the key factors influencing its future sales?

Market share erosion from newer drugs, patent expirations, and the absence of innovation are primary factors.

---

References

1. IQVIA, Global Ophthalmic Market Report 2022.
2. United States Patent and Trademark Office, Patent Status of Carbachol 2000-2022.
3. McKinsey & Company, Ophthalmic Drug Market Overview 2022.